NCT06177821 is a NA clinical trial of Rezum® in Prostatic Hyperplasia of the Medial Lobe, sponsored by Seoul National University Hospital.

Who is sponsoring NCT06177821?

NCT06177821 is sponsored by Seoul National University Hospital.

What drugs are being tested in NCT06177821?

Interventions in NCT06177821: Rezum®.

What condition does NCT06177821 study?

NCT06177821 studies Prostatic Hyperplasia of the Medial Lobe.

Is NCT06177821 still recruiting?

NCT06177821 is currently recruiting now. Last updated 19 April 2024.

Last reviewed 2024-04-19 · How we verify

NCT06177821

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Rezum for 30-80ml Patients With Moderate-severe LUTS to Study Surgical Principles for Median Lobe Enlargement

Recruiting now NA Last updated 19 April 2024

What this trial tests

NA trial testing Rezum® in Prostatic Hyperplasia of the Medial Lobe in 44 participants. Currently enrolling.

Timeline

3 June 2024

Primary endpoint
17 June 2024

30 December 2025

Quick facts

Lead sponsor	Seoul National University Hospital
Phase	NA
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	44
Start date	3 June 2024
Primary completion	17 June 2024
Estimated completion	30 December 2025
Sites	1 location across South Korea

Drugs / interventions tested

Rezum®

Conditions studied

Prostatic Hyperplasia of the Medial Lobe — all drugs for Prostatic Hyperplasia of the Medial Lobe →

Sponsor

Seoul National University Hospital

Who can join

Adults 50 to 85, male only, with Prostatic Hyperplasia of the Medial Lobe. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study was created to determine the safety and efficacy of treating prostatic hyperplasia with or without prominent median lobe enlargement with the REZUM technique. The systematic implementation of decisions for the location, vapor time, and the number of injections contributes to the Rezum procedure configuration for the median lobe treatment being safer and standardizer.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other Seoul National University Hospital trials

Trials by the same sponsor.

NCT07262944 — EOI Block in Otoplasty With Rib Cartilage Graft · NA · recruiting
NCT07464210 — Nemtabrutinib, Bortezomib, and Rituximab for WM · Phase 2 · not yet recruiting
NCT07550803 — Effect of Intraoperative Dexamethasone on Early Postoperative Sleep Quality in Patients Undergoing Nasal Surgery · NA · not yet recruiting
NCT07522138 — Home-based Self-exercise in Patients With Parkinson's Disease: A Feasibility Study · NA · not yet recruiting
NCT07476651 — Scout Dose of Resin Microspheres · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06177821 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Seoul National University Hospital
Last refreshed: 19 April 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06177821.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing